A Pilot Phase II Study of Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation.

Trial Profile

A Pilot Phase II Study of Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 30 Jun 2017

At a glance

  • Drugs Antithymocyte globulin (Primary) ; Rituximab (Primary) ; Sirolimus (Primary) ; Tacrolimus (Primary) ; Tacrolimus (Primary)
  • Indications Graft-versus-host disease
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Most Recent Events

    • 27 Nov 2012 Status changed from recruiting to suspended as reported by ClinicalTrials.gov .(NCT01116232).
    • 27 Nov 2012 Status changed from recruiting to suspended as reported by ClinicalTrials.gov .(NCT01116232).
    • 30 Jul 2012 Last checked against ClinicalTrials.gov record (NCT01534767).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top